230 related articles for article (PubMed ID: 24865428)
1. Four individually druggable MET hotspots mediate HGF-driven tumor progression.
Basilico C; Hultberg A; Blanchetot C; de Jonge N; Festjens E; Hanssens V; Osepa SI; De Boeck G; Mira A; Cazzanti M; Morello V; Dreier T; Saunders M; de Haard H; Michieli P
J Clin Invest; 2014 Jul; 124(7):3172-86. PubMed ID: 24865428
[TBL] [Abstract][Full Text] [Related]
2. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
[TBL] [Abstract][Full Text] [Related]
3. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
4. Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation.
Murray DW; Didier S; Chan A; Paulino V; Van Aelst L; Ruggieri R; Tran NL; Byrne AT; Symons M
Br J Cancer; 2014 Mar; 110(5):1307-15. PubMed ID: 24518591
[TBL] [Abstract][Full Text] [Related]
5. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
7. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
[TBL] [Abstract][Full Text] [Related]
9. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
10. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
[TBL] [Abstract][Full Text] [Related]
11. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
[TBL] [Abstract][Full Text] [Related]
13. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Chao KL; Tsai IW; Chen C; Herzberg O
PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
[TBL] [Abstract][Full Text] [Related]
15. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
16. Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET.
Saunders JT; Kumar S; Benavides-Serrato A; Holmes B; Benavides KE; Bashir MT; Nishimura RN; Gera J
J Neurooncol; 2023 May; 163(1):207-218. PubMed ID: 37162666
[TBL] [Abstract][Full Text] [Related]
17. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
18. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of the activation of c-MET receptor.
Uchikawa E; Chen Z; Xiao GY; Zhang X; Bai XC
Nat Commun; 2021 Jul; 12(1):4074. PubMed ID: 34210960
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.
Rubin JS; Day RM; Breckenridge D; Atabey N; Taylor WG; Stahl SJ; Wingfield PT; Kaufman JD; Schwall R; Bottaro DP
J Biol Chem; 2001 Aug; 276(35):32977-83. PubMed ID: 11435444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
